229 related articles for article (PubMed ID: 29721042)
1. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
2. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
[TBL] [Abstract][Full Text] [Related]
6. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
[TBL] [Abstract][Full Text] [Related]
8. Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries.
Milloy N; Kirker M; Unsworth M; Montgomery R; Kluth C; Kearney M; Chang J
Clin Genitourin Cancer; 2024 Feb; 22(1):e136-e147.e1. PubMed ID: 37945404
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
10. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
[TBL] [Abstract][Full Text] [Related]
11. Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Aguin S; Carral A; Iglesias L; Pena C; Molina A; Costa M; Covela M; Gomez JG; Arroyo RG; Huidobro G; Simo RV; Medina A
Cancer Diagn Progn; 2023; 3(2):264-271. PubMed ID: 36875311
[TBL] [Abstract][Full Text] [Related]
12. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
13. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
[TBL] [Abstract][Full Text] [Related]
15. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
[TBL] [Abstract][Full Text] [Related]
18. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
19. Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis.
Holmsten K; Dohn L; Jensen NV; Shah CH; Jäderling F; Pappot H; Ullén A
Oncol Lett; 2016 Aug; 12(2):1293-1300. PubMed ID: 27446429
[TBL] [Abstract][Full Text] [Related]
20. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
